KEYSER D JEFFREY 4

4 · Lantern Pharma Inc. · Filed Sep 23, 2025

Form 4

Period: 2025-09-19

Director

Transactions

Award
Stock Option (Right to Buy)
2020-06-15+9,135→ 9,135 total
Exercise: $5.04Exp: 2030-06-14→ Common Stock (9,135 underlying)
Award
Stock Option (Right to Buy)
2021-11-04+3,200→ 3,200 total
Exercise: $5.04Exp: 2031-11-03→ Common Stock (3,200 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2020-06-15−9,135→ 0 total
Exercise: $15.00Exp: 2030-06-14→ Common Stock (9,135 underlying)
Disposition to Issuer
Stock Option (Right to Buy)
2021-11-04−3,200→ 0 total
Exercise: $10.32Exp: 2031-11-03→ Common Stock (3,200 underlying)

Footnotes (2)

[F1]The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on June 15, 2020 and provides for vesting in equal monthly increments over a 36-month period commencing July 15, 2020.
[F2]The two reported transactions involve an amendment of an outstanding option for purposes of reducing the option exercise price, resulting in the cancellation of the "old" option and the grant of a replacement option. The option was originally granted on November 4, 2021 and provides for vesting in equal monthly increments over a 36-month period commencing December 4, 2021.

Documents

1 file